Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

The burgeoning field of diabetes management has witnessed the rise of GLP-3 receptor agonists, representing a significant class of therapeutics. Comparing these medications requires a thorough look at their respective profiles. Semaglutide, for example, offers a once-weekly dosing schedule, appealing to patients seeking ease, while tirzepatide, a d

Retaglutide and tirzepatide represent innovative class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are o